Clinical data | |
---|---|
Other names | SH-434; 17α-Propylmesterolone; 17β-Hydroxy-1α-methyl-17α-propyl-5α-androstan-3-one |
Routes of administration | Topical |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.071.904 |
Chemical and physical data | |
Formula | C23H38O2 |
Molar mass | 346.555 g·mol−1 |
3D model ( JSmol) | |
| |
|
Rosterolone ( INN ) (developmental code name SH-434), also known as 17α-propylmesterolone or 1α-methyl-17α-propyl-5α-androstan-17β-ol-3-one, is a steroidal antiandrogen which was first described in 1984 and was developed for topical administration but was never marketed. [1] [2] It has shown some efficacy in the treatment of acne, and lacks systemic effects with either topical or systemic administration. [3] [1] [2] Rosterolone is a derivative of mesterolone, which, in contrast, is an androgen and anabolic steroid.[ citation needed]